theMednetRegister
JCO precision oncology 2019
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.   

Related Questions

Are you treating patients with RET-fusion+ metastatic NSCLC with RET inhibitors as the first line of therapy regardless of PD-L1 expression?
Are there scenarios in which you would proceed with checkpoint inhibitor for PDL1+ disease before having full molecular testing results?
New comment by Medical Oncologist at Conway Regional Health System ( April 18, 2023)
How would you approach if the patient developed grade 4 hepatotoxicity and that will not recover and had to wait for 3-4 weeks?
Copyright © 2025 theMednet
All Rights Reserved.